Effects of complete immunotoxin lesions of the cholinergic basal forebrain on fear conditioning and spatial learning.
Administration of muscarinic cholinergic antagonists such as scopolamine impairs the acquisition of contextual fear conditioning, but the role of the basal forebrain (BF) cholinergic system in consolidation is unclear. To test the hypothesis that BF cholinergic neurons are critical for acquisition and consolidation of fear conditioning, male Sprague-Dawley rats with 192 IgG-saporin lesions of the entire cholinergic BF made either before or after fear conditioning were tested for conditioned fear to context and tone by assessing freezing and 22 kHz ultrasonic vocalization (USV) responses. Spatial learning in a 1-day water maze task provided a comparison for effects of the BF lesions on fear conditioning. In the test phase, neither pre-training nor posttraining BF lesions affected freezing to the context or tone. During both training and testing, pre-lesioned rats were impaired in production of USVs associated with fear. Postlesioned rats emitted fewer USVs only during testing. Acquisition of a spatial water maze task was mildly impaired in lesioned rats, although probe trial and cued performance was unimpaired. Nevertheless, these data suggest that conditioned fear-induced USVs are more sensitive to the loss of BF cholinergic neurons than is conditioned fear-induced freezing. The failure of BF cholinergic lesions to impair contextual fear conditioning indicates that scopolamine-induced impairments in fear conditioning may not be mediated by affecting cholinergic input to the hippocampus and neocortex.
Frick
Karyn M
KM
Department of Psychology and Interdepartmental Neuroscience Program, Yale University, New Haven, Connecticut 06520, USA. karyn.frick@yale.edu
Kim
Jeansok J
JJ
Baxter
Mark G
MG
D000818:Animals; D000911:Antibodies, Monoclonal / Q000633:toxicity; D002795:Choline O-Acetyltransferase / Q000378:metabolism; D003216:Conditioning, Operant / Q000187:drug effects*; D003463:Cues; D005239:Fear / Q000502:physiology*; D005968:Glutamate Decarboxylase / Q000378:metabolism; D007150:Immunohistochemistry; D000922:Immunotoxins / Q000633:toxicity*; D008297:Male; D018782:Maze Learning / Q000187:drug effects*; D008568:Memory / Q000187:drug effects; D009699:N-Glycosyl Hydrolases; D010275:Parasympathetic Nervous System / Q000187:drug effects*; D016548:Prosencephalon / Q000187:drug effects*; D051381:Rats; D017207:Rats, Sprague-Dawley; D054789:Ribosome Inactivating Proteins, Type 1; D000076985:Saporins; D014828:Vocalization, Animal / Q000502:physiology
C085696:192 IgG-saporin; D000911:Antibodies, Monoclonal; D000922:Immunotoxins; D054789:Ribosome Inactivating Proteins, Type 1; D002795:Choline O-Acetyltransferase; D009699:N-Glycosyl Hydrolases; D000076985:Saporins; D005968:Glutamate Decarboxylase